United Therapeutics Corporation (UTHR) Shares are Up 8.62%

United Therapeutics Corporation (UTHR) : Traders are bullish on United Therapeutics Corporation (UTHR) as it has outperformed the S&P 500 by a wide margin of 7.52% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 8.69%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 8.62% in the last 1 week, and is up 11.13% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 8.82% and the 50-Day Moving Average is 9.08%. United Therapeutics Corporation is up 15.03% in the last 3-month period. Year-to-Date the stock performance stands at -22.73%.


United Therapeutics Corporation (NASDAQ:UTHR): stock turned positive on Friday. Though the stock opened at $118.97, the bulls momentum made the stock top out at $122.23 level for the day. The stock recorded a low of $118.185 and closed the trading day at $121.01, in the green by 1.70%. The total traded volume for the day was 868,769. The stock had closed at $118.99 in the previous days trading.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.